Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 8/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SLC13A2 | Q13183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL8371200 | 0.93 | ALDH1A1 (0.52) | ALDH1A1LMNAHSD17B10KDM4ETSHR | |
| Citric Acid SCHEMBL1768036 | 0.85 | ALDH1A1 (0.56) | ALDH1A1LMNAHSD17B10KDM4ETSHR | |
| Citric Acid SCHEMBL28740294 | 0.84 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10MAPTMEN1 | |
| SCHEMBL30384961 | 0.84 | ALDH1A1 (0.60) | ALDH1A1LMNAKDM4ETSHRMAPT | |
| SCHEMBL72953 | 0.84 | ALDH1A1 (0.60) | ALDH1A1LMNAKDM4ETSHRMAPT | |
| Citric Acid SCHEMBL4292973 | 0.84 | ALDH1A1 (0.60) | ALDH1A1LMNAKDM4ETSHRMAPT | |
| Citric Acid SCHEMBL2490516 | 0.82 | ALDH1A1 (0.58) | ALDH1A1LMNAHSD17B10KDM4ETSHR | |
| SCHEMBL433131 | 0.82 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4ETSHRMAPT | |
| Ammonia Solution, Strong SCHEMBL29179739 | 0.82 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4ETSHRMAPT | |
| SCHEMBL16737228 | 0.82 | ALDH1A1 (0.58) | ALDH1A1LMNAKDM4ETSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119112098-A | Device and storage medium for detecting local fibrosis degree of rectal cancer after new auxiliary radiotherapy and chemotherapy in situ in real time | 严俊 | 2024-12-13 | — | — | CN | disclosed |
| CN-114007606-A | Process for the synthesis of furoimidazopyridines, polymorphs and polymorphs of the salt | 杭州高光制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020244349-A1 | METHOD FOR SYNTHESIZING FUROIMIDAZOPYRIDINE COMPOUND, POLYMORPHIC SUBSTANCE AND POLYMORPHIC SUBSTANCE OF SALT | 广州高瓴制药有限公司 | 2020-12-10 | — | — | WO | disclosed |
| CN-107907395-B | Method for evaluating paracancerous collagen tissue of early gastric cancer resection specimen | 南方医科大学南方医院 | 2020-10-20 | — | — | CN | disclosed |
| CN-107941765-B | Evaluation method of gastric serosa surface collagen tissue of gastric cancer resection specimen | 南方医科大学南方医院 | 2020-08-21 | — | — | CN | disclosed |
| CN-107941760-B | Evaluation method of collagen tissue at incisional margin of rectal cancer resection specimen | 南方医科大学南方医院 | 2020-06-30 | — | — | CN | disclosed |
| CN-110305042-A | N α-fluorenylmethyloxycarbonyl-N γ-(4,4- dimethyl -2,6- dioxo hexamethylene subunit) ethyl-butyric acid preparation method | 吉尔生化（上海）有限公司 | 2019-10-08 | — | — | CN | disclosed |
| CN-108752343-A | A kind of preparation method of caffeine citrate | 江苏天晟药业股份有限公司 | 2018-11-06 | — | — | CN | disclosed |
| CN-107941765-A | The stomach serosa surface collagen tissue evaluation method of Operated Specimens of Gastric Carcinoma | 南方医科大学南方医院 | 2018-04-20 | — | — | CN | disclosed |
| CN-107941760-A | Collagen tissue evaluation method at the incisxal edge of resection of rectal sample | 南方医科大学南方医院 | 2018-04-20 | — | — | CN | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| US-6288237-B1 | PLANT PROTECTION. IMMUNOSUPPRESSION AND/OR BE USED TO COMBAT MALIGNANT TUMOURS; THEY ARE PARTICULARILY PREFERRED AS CYTOSTATIC AGENTS. | GESELLSCHAFT FUR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) (DE) | 2001-09-11 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1007515-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| US-6001814-A | TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPSISMULTIPLE ORGAN FAILURE | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5134138-A | ANTIBIOTICS | SHIONOGI & CO., LTD. (JP) | 1992-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MEN1 4595/4885ALDH1A1 286/4885LMNA 3504/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MEN1 4595/4885ALDH1A1 286/4885LMNA 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.